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(TNM) classification don-small-cell lung cancer (NSCLC) the tumour–node–metastasis
eveloped by Pierre Denoix replaced in 1968 the Veterans Administra-Anatomical cancer extent is an important predictor of prognosis and determines treat-
tion Lung cancer Group (VALG) classification, which was still in use for small-cell lung
cancer (SCLC). Clifton Mountain suggested several improvements based on a database
of mostly surgically treated United States (US) patients from a limited number of centres.
This database was pivotal for a uniform reporting of lung cancer extent by the American
Joint Committee of Cancer (AJCC) and the International Union against Cancer (IUCC), but
it suffered increasingly from obsolete diagnostic and staging procedures and did not
reflect new treatment modalities. Moreover, its findings were not externally validated
in large Japanese and European databases, resulting in persisting controversies which
could not be solved with the available database. The use of different mediastinal
lymph-node maps in Japan, the (US) and Europe facilitated neither the exchange nor
the comparison of treatment results.
Peter Goldstraw, a United Kingdom (UK) thoracic surgeon, started the process of updating
the sixth version in 1996 and brought it to a good end 10 years later. His goals were to
improve the TNM system in lung cancer by addressing the ongoing controversies, to val-
idate the modifications and additional descriptors, to validate the TNM for use in staging
SCLC and carcinoid tumours, to propose a new uniform lymph-node map and to investi-
gate the prognostic value of non-anatomical factors. A staging committee was formed
within the International Association for the Study of Lung Cancer (IASLC) – which super-
vised the collection of the retrospective data from >100,000 patients with lung cancer –
treated throughout the world between 1990 and 2000, analyse them with the help of solid
statistics and validate externally with the Surveillance, Epidemiology and End Results
(SEER) database.
The ten modifications and the mediastinal lymph-node map – which were proposed in
2007 and adopted by the AJCC and IUCC in their respective seventh revision of the
TNM system – were implemented as of 2010 and were rapidly adopted by the thoracic
oncology community and cancer registries. As expected, not all controversies could be
fully addressed, and the need for a prospective data set containing more granular
information was felt early on. This data set of 25,000 consecutive incident cases will
form the base for the eighth revision in 2017 and is currently being collected. Other
threats are the role of stage migration and the increasing number of biological factors
interfering with disease extent for prognostication. The latter issue will be addressed
by the creation of a prognostic index, including several prognostic factors, of which
stage will be one.For the time being, the seventh TNM classification is considered
the gold standard for the description of disease extent, initial treatment allocationgium. Tel.:
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 5 0 –1 5 8 151and the reporting of treatment results. The uniform use of the TNM descriptors and
the lymph-node map by all involved in lung cancer care is to be considered a process
indicator of quality.
Copyright  2013 ECCO - the European CanCer Organisation. All rights reserved.1. Introduction
1.1. Background
Prognostication of outcome is of all ages and a distinguish-
ing feature of mankind. Similarly, linking features of a tu-
mour to its natural history has been reported since
pharaonic times. Surgical resection often being the only
modality available at presentation in those days, anatomical
tumour extent was from the early days associated with out-
come and became a pivotal driver in treatment allocation
and evaluation. It was the seminal work of the French sur-
geon Pierre Denoix in the 1940s and 1950s that led to the
creation of the committee on Clinical Stage Classification
and Applied Statistics within the Union for International
Cancer Control (UICC), and the development of the tu-
mour–node–metastasis (TNM) classification which is still
the current gold standard for the anatomical staging of most
solid malignant neoplasms.
In the first edition of the UICC manual, lung cancer was
classified with ‘other sites’, although several publications
had already addressed the relationship between anatomical
extent and outcome [1–4]. The United States (US) surgeon Clif-
ton Mountain progressively introduced new denominators
and substages based on the analysis of a mostly surgical data-
base from US institutions [5–10]. Although some of his data
were externally validated in other cancer registry series, it be-
came increasingly clear by 1996, when the sixth edition of the
lung cancer TNM classification appeared, that a further
refinement had become necessary, that the revision proce-
dure had several limitations and that there was a growing
need for uniformity in the nomenclature used to describe no-
dal stations [11–13]. Globally, two nodal maps were in use: the
Mountain/Dressler [14] used in North America and parts of
Europe, and the Japanese Naruke map [15] used in Asia and
other parts of Europe.
The International Association for the Study of Lung Can-
cer (IASLC) undertook the ambitious International Staging
Project in which an international database was assembled,
consisting of more than 67,000 cases of lung cancer, treated
between 1990 and 2000 by all modalities of care and col-
lected retrospectively from 46 data sources from more than
19 countries around the world [16]. The size of this database
allowed validation, both internal and external, of the revi-
sions to descriptors and stages to a degree unprecedented
in the history of TNM. The IASLC staging project has deliv-
ered a seventh edition of the TNM classification for lung
cancer that aligns stage with prognosis more closely than
before [17]. It was enacted on January 1, 2010, and all of
its proposed revisions were subsequently accepted by
the UICC [4] and the American Joint Committee on Cancer
(AJCC) [18,19].1.2. The seventh edition of the TNM classification of lung
cancer
The major modifications are listed in Table 1 [20,21]. Tumour
size has been given added importance [22]. New T size cut-
points were originally identified in the node-negative, patho-
logically staged patients having undergone complete resec-
tion, but were also shown to be valid in the clinically staged
patient cases: 2 cm separating T1a and T1b, 5 cm dividing
T2a from T2b and size >7 cm becoming a T3 descriptor for
the first time. If these larger tumours are node-negative, they
move to stage IIA if T2b N0 M0 and to stage IIB if T3 N0 M0;
previously these were all considered stage IB [23].
When additional tumour nodules are found synchro-
nously with a known lung cancer, the distinction between
lung metastases and multiple primary tumours has relied
on clinical and morphological criteria [24]. The distinction is
easy when tumours are of different cell types, and there is lit-
tle debate if tumours are of the same cell type but associated
with separate areas of carcinoma in situ, although in most
cases this is confirmed only after resection. The other criteria
are more problematic: the tumours should be distinct and
separate, should lie in different segments, lobes or lungs,
and should not be associated with any nodal involvement in
an area of common lymphatic drainage. Although 20 years la-
ter there was a suggestion to modify these criteria by the
addition of DNA ploidy [25], the criteria have otherwise re-
mained unchanged despite the enormous advances in imag-
ing, histopathology, immunohistochemistry, mutational
analysis and biopsy techniques since that time. In the latest
edition, the distinction between synchronous primary tu-
mours of similar histological appearance and metastases
has been clarified, and the pathologist has been given a cen-
tral role in this process, allowing the distinction to be made
on biopsy specimens before a decision is taken on the most
appropriate treatment. Multiple tumours of similar histologi-
cal appearance may now be considered to be synchronous
primary tumours if in the opinion of the pathologist – on
the basis of features such as differences in morphology,
immunohistochemistry and/or molecular studies or, in the
case of squamous cancers, on the basis of association with
carcinoma in situ – they represent different subtypes of the
same histopathological cell type. Such cases should also have
no evidence of mediastinal nodal metastases or of nodal
metastases within a common nodal drainage. Clearly, if the
management of any particular patient is dependent on this
distinction, the biopsy of more than one lesion may be neces-
sary. In other situations, or where this is considered imprac-
tical, one may fall back on a generic principle of giving the
patient the benefit of the doubt and assigning the lower T cat-
egory and/or stage. Multiple synchronous primary tumours
should be staged separately. These may be recorded sepa-
Table 1 – Ten modifications in the tumour–node–metastasis (TNM) of lung cancer in the seventh UICC classification [17–20].
Summary of change Details of new definition References
1 Subclassification of T1/2 according to
largest tumour diameter
62 cm: T1a; 2.1–3.0 cm: T1b; 3.1–5.0 cm:
T2a; 5.1–7.0 cm: T2b; >7 cm: T3
[22]
2 Reclassification of synchronous additional
tumour nodules (ATNs)
See Table 2 [22]
3 New borders for mediastinal lymph-node
stations
[28]
4 Reclassification of malignant pleural/
pericardial effusion
M1a [26]
5 Subclassification of M1 Limited to thorax: M1a; extrathoracic
spread: M1b
[26]
6 Use of TNM in SCLC and carcinoid tumours [35–37]
7 Appropriate (sub)stage regrouping (Fig. 1) T2bN0 becomes stage IIA instead of IB;
T2aN1 becomes IIA instead of IIB; T4N0/1
becomes IIIA instead of IIIB
[23]
8 Elimination of Mx descriptor The clinical assessment of metastasis can
be based on physical examination alone
(cM0/1); pM0 should be restricted to autopsy
cases. Else, the pathologist should refer to
cM
[19]
9 Optional descriptor for pleural (Pl) invasion Tumour growth under internal elastic layer:
Pl0 – through elastic layer but not abutting
pleural surface: Pl1, T upgrading to at least
T2a – abutting pleural surface: Pl2; T
upgrading to at least T2a – in parietal
pleura: Pl3; T upgrading to at least T3 –
cannot be assessed: PlX
[38]
10 Optional descriptor for perineural (Pn)
invasion
Pn0: no perineural invasion, Pn1: perineural
invasion, PnX: perineural invasion cannot
be assessed
[19]
152 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 5 0 –1 5 8rately, or if a single TNM category is required, the highest T
category and stage of disease should be assigned and the
multiplicity of the lesions categorised as (m), or the number
of tumours should be indicated in parentheses, for example:
T2(m) or T2(5). If the lesions are concluded to be metastases,
then the appropriate T or M category will be dependent on the
site of the nodules (Table 2). If in the same lobe as the primary
they are now classified as T3 and, when associated with node
negativity, are stage IIB. When associated with N1 or N2 dis-
ease they are now classified as stage IIIA, not IIIB. Tumours
associated with additional nodules in other ipsilateral lobe(s)
have been reclassified as T4 rather than M1. When associated
with N0 or N1, these patient cases should be designated as
stage IIIA, and with N2 or N3 as stage IIIB. Tumours associated
with additional nodules in the contralateral lung remain M1
but have been reclassified as M1a.
The T4 descriptor remained unchanged, but when associ-
ated with N0 or N1 disease, it was down-staged to stage IIIA,
not IIIB. Tumours associated with malignant pleural/pericar-
dial effusion or pleural/pericardial nodules have been reclas-Table 2 – The fate over time of multiple synchronous primary t
UICC 5, recommendation [8] UICC
Same lobe as primary
tumour
Tn +1 T4; a
Same lung, other lobe T4: at least stage IIIB M1: s
Other lung M1: stage IV M1: ssified as M1a rather than T4 [26]. These data reflect the
algorithm previously developed to treat patients with so-
called wet IIIB disease with systemic therapy. Tumours asso-
ciated with distant metastases have been reclassified as M1b.
Analysis of the IASLC database allowed validation of the
existing N categories, which were adopted without change
[27]. Both existing lymph-node maps were unified in the IAS-
LC nodal map [28], and the precise anatomical definitions of
each nodal station are now recognised by the UICC and AJCC
as the recommended means of describing regional lymph-
node involvement for lung cancer. An important modification
to both previous maps is the observation that the anatomical
and oncological midlines in the superior mediastinum no
longer coincide. The oncological midline deviates to the left
lateral border of the trachea at the thoracic inlet and returns
to the midline at the carina. Thus, all nodes in the superior
mediastinum that lie anterior to the trachea are grouped with
right upper paratracheal station 2 and right lower paratrac-
heal station 4. Involvement of these nodes by a right-sided
tumour will now be classified as N2-disease, whereas for aumours.
6 [11–13] UICC 7 [17–20,22]
t least stage IIIB T3N0: stage IIB; 3N1/2: stage IIIA; T3N3:
stage IIIB
tage IV T4N0/1: stage IIIA; T4N2/3:stage IIIB
tage IV M1a: stage IV
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keeping with the observations of some Japanese colleagues
[29]. In addition, the concept of nodal zones has been intro-
duced, amalgamating adjacent nodal stations into larger ana-
tomic units. An exploratory analysis of the IASLC database
studied survival after complete resection in relation to the ex-
tent of node involvement using the zonal concept. Three
groups were identified, with significant differences in sur-
vival. Those with single-zone N1 disease had the best sur-
vival, at 48% over 5 years. Patients with multizone N2
disease had the worst survival, at 20% over 5 years. The third
group, with intermediate survival, consisted of patients with
multizone N1 (35% 5-year survival) and those with single-
zone N2-disease (34% 5-year survival). This refinement is
presently under investigation, in order to make the nodal
map of greater use to oncologists and radiologists, who are
frequently tasked with classifying more bulky nodal disease
that might transgress the boundaries of individual nodal
stations.
As many as 40% of the reports on lung cancer resection
specimens contains no information on mediastinal node
involvement [30]. It is known that the greater the number of
lymph nodes removed at thoracotomy, the higher the survival
rate [31,32], even if all nodes are shown to be negative, presum-
ably by increasing the certainty of the N0 classification [33]. The
development of an internationally agreed nodal classification
has allowed the reintroduction of minimum requirements for
nodal assessment at surgery and subsequent pathological
evaluation. In the latest edition of TNM, there is now an ex-
panded definition of complete resection (R0), which recom-
mends that at least six lymph nodes/nodal stations be
removed/sampled and confirmed on histology to be free of dis-
ease to confer pN0 status [34]. Three of these nodes/stationsFig. 1 – Stage groups according to tumour–node–metastasis (TNM
Detterbeck et al [20]. >7: diameter >7 cm; Inv: invasion; Satell: s
lung; Contr Nod: nodule in contralateral lung; Pl dissem: pleurashould be mediastinal, including the subcarinal nodes
(station 7) and three from N1 nodes/stations. It is hoped that
the setting of this basic standard will improve nodal assess-
ment and thereby the outcomes of pulmonary resection for
lung cancer.
The above mentioned modifications in T and N have led to
a migration of cases in between pre-existing (sub)stages
(Fig. 1): T2bN0 becomes stage IIA instead of IB; T2a N1 be-
comes IIA instead of IIB; T4N0/1 becomes IIIA instead of IIIB.
Small-cell lung cancer has always been excluded from the
TNM classification. However, the seventh edition is the first to
show that TNM has greater utility than the limited versus
extensive stage split commonly used in clinically staged pa-
tients as well as those treated surgically, especially as a strat-
ification factor in clinical trials of earlier-stage disease [35,36].
Although the TNM classification was already used in both the
typical and atypical variants of carcinoid tumours, the sev-
enth edition is the first to validate this practice [37].
There has never been an internationally agreed definition
of visceral pleural invasion (VPI). This created difficulties for
the IASLC staging project when attempting to define the inter-
relationship between VPI and other prognostic factors such as
tumour size. An internationally agreed definition was there-
fore developed, in which VPI is defined as ‘invasion beyond
the elastic layer including invasion to the visceral pleural sur-
face’ [38]. In addition, a comment was added recommending
the use of elastic stains when this feature is not clear on rou-
tine histology. With these refinements, VPI was carried for-
ward into the seventh edition without change, and the
IASLC proposed an optional more detailed classification of
pleural invasion, adapting the P category developed by the Ja-
pan Lung Cancer Society to create a PL classification [39,40].
The impact of visceral pleural invasion on survival according) descriptor and subgroups. Reprinted with permission from
atellite nodule in same lobe; Ipsi Nod: nodule in ipsilateral
l or pericardial dissemination.
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tion and confirmed its proposed Pl descriptor [41].
Other changes, generic to the seventh edition of UICC, are
the elimination of Mx and the introduction of a descriptor of
perineural invasion Pn.
1.3. Implications of the 7th edition
Several authors have addressed the magnitude of the impact
of the modifications on stage grouping. Van Meerbeeck et al
estimated that in the IASLC data set of 15,952 resected pa-
tients, the change of p-TNM staging classification from UICC
6 to 7 results in the net migration of 23% of resected cases:
stage pIB (–1326), stage pIIA (+2017), stage pIIB (±730), stage
pIIIA (+701), stage pIIIB (–745) and stage pIV (+83) (Fig. 2)
[42]. The magnitude of up- and down-migration is similar.
Substage migration resulted in an increase in 5-year survival
of 4% in p-IB and a decrease of 10% in p-IIIB. This stage migra-
tion should be accounted for when comparing outcome
across surgical series using different TNM classifications. In
a Norwegian cancer registry series from 2001–2005, the con-
cordance index was 0.68 for both editions, indicating no over-
all difference in their predictive accuracy [43]. In the seventhFig. 2 – (A) Stage migration from sixth to seventh tumour–node–
of stage migration on overall survival. Reproduced with permisedition, 211 (29%) stage IB patients migrated to stage II and
161 (48%) patients migrated from stage IIB to IIA. Stage migra-
tions could change the treatment for up to 326 (17.3%) of the
patients in this series [43].
1.4. Strengths
Lung cancer stage definitions have never been subjected to
such an intense validation process [44]. Internal validity was
addressed by visually assessing the consistency of Kaplan–
Meier curves across database types and geographic regions.
External validity was addressed by assessing the similarity
of curves generated using the population-based Surveillance
Epidemiology and End Results (SEER) cancer registry data to
those generated using the project database. Cox proportional
hazards regression was used to calculate hazard ratios be-
tween the proposed stage groupings with adjustment for cell
type, sex, age and region. Validation checks were robust, dem-
onstrating that the suggested staging changes were internally
and externally stable. Several series coming from cancer reg-
istries and surgical series have confirmed some or all of the
proposed modifications, adding supplementary external vali-
dation to the classification [45,46].metastasis (TNM) classification in resected cases. (B) Impact
sion from Van Meerbeeck et al [42].
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Taken together, the proposed changes are limited in number
and most are either intuitive or reflect modifications that
were already suggested in the analysis of cancer registries
or surgical series. As some of these series were included in
the IASLC database, these modifications are self-fulfilling.
With respect to the proposed boundaries for lymph-node
stations, they represent a clear improvement for surgeons,
but are not unambiguous for radiologists and echo-endosco-
pists. A recent ultrasonographic lymph-node map based on
the anatomical boundaries of the seventh UICC classification
might well resolve this issue [47]. The abovementioned
reshaping of mediastinal lymph-node borders will result in
an increase in so-called ‘minimal N2’, limited to a single sta-
tion. The magnitude of this phenomenon has not yet been re-
ported. Furthermore, stage IIIA, which used to be
heterogeneous in the sixth classification, becomes a cocktail
of six different T/N combinations.
Even a database of 67,000+ patients was not able to vali-
date all the descriptors that had accrued within previous edi-
tions of TNM. One should remember, however, that many of
these data were not originally defined for the purpose of eval-
uating the staging system, but with some other scientific
questions in mind. Their prognostic role was not always con-
firmed by multivariate analysis. Among the T descriptors that
need further study are:
(1) The best way to assess tumour size clinically: measur-
ing a single diameter, measuring the greatest diameter
or measuring two or three dimensions. Computed
tomography (CT) screening has accelerated the devel-
opment of volumetric software, adding to the debate
as to how best to determine tumour size, and whether
or not volume is preferable over size [48].
(2) The non-size-based descriptors of T2/3 as hilar atelec-
tasis, obstructive pneumonitis and the cytology-nega-
tive paramalignant pleural effusion (not considered as
a T-modifying condition) [49]. It is hoped that the use
of [18]fluorodeoxyglucose–positron emission tomogra-
phy (FDG-PET) scanning may help unravel the inflam-
matory and neoplastic elements.
(3) The split of which invasion to adjacent structures is
assigned to T3 or to T4 could not be answered because
there were too few patient cases in which the precise
descriptor justifying the T3 or T4 category was
recorded, and even fewer in which all of the other
descriptors were known to be absent.
(4) The extent of dissemination was only partly addressed
by the introduction of M1a. The recently increasing inter-
est in the outcome of oligometastatic disease could not
be translated into a separate descriptor for this entity.Other details and areas in which ambiguities and difficul-
ties exist have been reviewed [50].1.6. Threats
Although the data are definitely more recent than in previous
TNM editions, they still are from the past century and do notreflect present-day staging and treatment paradigms, where-
in FDG-PET and endoscopic ultrasound are now standard
staging techniques for the M and N descriptors. It has been
shown in several series that the introduction of both tech-
niques has significantly improved the accuracy of clinical
staging and upstaged the stage distribution at diagnosis,
hence changing treatment algorithms and improved stage-
specific outcomes [51]. This process of improved stage-spe-
cific survival has been described previously at the occasion
of a previous revision of the lung cancer TNM [52]. This so-
called Will Rogers phenomenon has been observed in stage
III patients, where the outcome was significantly ‘improved’
by the occurrence of PET staging [53–55].
Whereas pathological staging has a prognostic signifi-
cance, clinical staging is meant to help the clinician in treat-
ment allocation. The interaction between better staging
techniques and improved treatment strategies does not allow
the expectation that revisions in staging classification will
necessarily translate into a better overall outcome, unless
over decades. It is controversial whether treatment should
necessarily follow a stage change, as stage should not be con-
sidered a ‘cook book’ for treatment allocation. The issue is
particularly critical for the ‘down-staged’ additional tumour
nodules, single zone N2 and T4N0 cases as described before.
The analysis of the IASLC database was heavily influenced
by surgical cases and pathological staging and cannot neces-
sarily be extrapolated to clinical staging, which has been re-
ported to be inaccurate [56]. Besides, individual patients
with more advanced stages but an inherent indolent biologi-
cal behaviour of their tumour have been reported to profit
from more ‘aggressive’ surgical or radiotherapeutic ap-
proaches, whilst others with more limited stage will be given
symptomatic care for reasons such as poor performance or
comorbidity. pT2pN0 tumours with a diameter of 5.5 cm were
previously considered pIB and hence not candidates for adju-
vant chemotherapy. The same case would now be considered
pT2bpN0 and staged pIIA and would be offered adjuvant
treatment. We should remember that the data supporting
adjuvant chemotherapy after complete resection were gener-
ated from trials using the sixth edition of the TNM classifica-
tion, and that offering adjuvant chemotherapy to ‘reclassified’
stage pIB, pII and pIIIA completely resected cases is therefore
not evidence-based [57,58]. A recent pooled analysis of pa-
tient cases from two multicentre trials using the size cut-
points of the seventh edition of the TNM classification was
unable to identify subgroups of patients who did or did not
derive significant benefit from adjuvant chemotherapy after
complete resection based on tumour size [59]. Prospective
data from large adjuvant chemotherapy trials are necessary
before clinical guidelines regarding management of surgically
resected node-negative non-small-cell lung cancer (NSCLC)
can be updated to reflect the changes introduced.
1.7. Opportunities
The aforementioned weaknesses and threats offer some chal-
lenging opportunities for further research. All unproven
descriptors and hypotheses are carried forward for close eval-
uation in a 25,000-patient prospective database being col-
lected for the future TNM- revision foreseen for 2016 [60].
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(GGOs) deserves special attention as these are increasingly
found at CT-scan screening, with or without a solid compo-
nent. By histological definition, in-situ adenocarcinoma is de-
fined only for GGOs with a diameter of <3 cm [61]. GGOs are
considered non-invasive adenocarcinoma in situ, whilst only
the associated solid component is presumed to be invasive.
Those P3 cm are no longer ‘adenocarcinoma in situ’ and re-
late to a T2 description. However, their biological behaviour
is less aggressive, suggesting that the measurement of the
GGO in the evaluation of tumour size be discarded, analo-
gously to the situation in breast cancer, where the tumour
is coded for the invasive component only.
The concept that overall burden of lymph nodal disease
(nN) might be more important than the anatomical location
of the involved nodes comes from similar observations in
oesophageal cancer. In a large retrospective series of resected
Japanese patients, it was observed that the number of lymph
nodes involved was a more precise prognostic determinant
than their location and could be considered for the nodal stage
classification as is done in other organs [62]. However, it is dif-
ficult to assess the exact number of the metastatic lymph
nodes pre-operatively, and a uniform definition for pre- and
post-operative assessment is preferable to avoid confusion. Be-
sides, fragmentation of lymph nodes produced during the
operation might result in an overestimation of the survival risk.
Pleural lavage cytology (PLC) is performed by some sur-
geons as the initial step after performing thoracotomy. In pa-
tients without overt effusion or pleural dissemination, a
recent meta-analysis confirmed that PLC shown to be positive
for cancer cells has an adverse and independent prognostic
impact after complete resection [63]. When PLC is positive,
the resection should be classified as R1(cy+). Sophisticated
immunohistochemical and genetic techniques permit the
detection of very small tumour deposits. A micrometastasis
as defined by the UICC and AJCC usually is detected by routine
haematoxylin and eosin staining, and typically mitoses and
invasion are seen [64]. Such micrometastases in nodes or dis-
tant sites are counted as positive and denoted by the symbol
(mi): for example, cN1(mi) or pN2(mi). However, the prognos-
tic impact was not evaluated in the IASLC staging analysis.
Isolated tumour cells (ITCs) are small clumps of tumour cells
typically without mitoses or vascular or lymphatic invasion.
ITCs within nodes (or distant sites) are not counted in the
stage classification and should be coded as N0 (or M0), regard-
less of node level harbouring the ITC, for example, pN0(i 1) or
pN0(mol 1). The prognostic value of ITCs has been inconsis-
tent. The same applies for circulating tumour cells [65].
A staging classification describes the anatomical extent of
a tumour, disregarding its biological behaviour. Stage is hence
only one of several prognostic factors to be accounted for in
prognostication, together with one or several biological mark-
ers which have been repeatedly linked with the outcome
regardless of the treatment established [66]. Logistic regres-
sion techniques will allow the construction of a composite
prognostic index in which different independent predictive
factors are weighted and available for use in a nomogram or
electronic outcome calculator [67,68].
Quality of health care is of increasing concern and interest.
Indicators can help to describe the structural environment,the quality of the staging process and its outcome. The TNM
descriptors and denominators lend themselves well as indi-
cators of staging. Examples are the extent of intra-operative
lymph-node sampling as an indicator of quality of the resec-
tion, clinicopathological correlation of resected tumours as a
measure of staging accuracy and outcome according to stage.
It is expected that these and others will be increasingly used
to peer review medical practice.2. Conclusion
The publication of the seventh edition of the lung cancer
TNM classification has been variously applauded as a ‘seis-
mic shift in staging’ by some or dubbed a laudable effort
in ‘lumping, splitting and sorting’ by others [69,70]. It is con-
sidered a quantum leap forward in patient care, being based
on an unprecedented large international database and
involving extensive analysis and validation. Inevitably, the
system is also more complex and far from perfect; with
more refined data comes greater ability to discern granular
details. This necessitates more layers of classification, man-
ifested by additional new descriptors. As with any complex
system, rules that seem clear in one context can seem awk-
ward or conflicting in another. Implementation brings ambi-
guities to light. A clear knowledge of the details and
difficulties should help to promote appropriate application
and realisation of the full benefits of the new stage classifi-
cation system.
There is much work to be done to answer these questions
before the next revision scheduled for 2016. The IASLC is
determined that over future revisions these shortcomings will
be addressed as prospective data are accrued. The seventh
edition of TNM in its present form remains, however, a surro-
gate for the anatomical extent of a tumour and a sequel to
previous revisions. Unless we succeed in the prequel of build-
ing a composite prognostic index, including an increasing
number of factors and inclusive biomarkers, ‘we might con-
sider the TNM method for lung cancer staging to be similar
to ‘brownstone’ remnants of historical interest and accept
biological markers of disease extent and behaviour as the
skyscrapers of our future’[71].Conflict of interest statement
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